logo
Share SHARE
FONT-SIZE Plus   Neg

Taro Says Its Special Committee Of Board Rejects Proposal From Sun Pharma

Taro Pharmaceutical Industries Ltd. (TARO) announced that the Special Committee of its Board of Directors unanimously rejected the October 18, 2011 unsolicited, non-binding offer from Sun Pharmaceutical Industries Ltd. to buy all of the issued and outstanding shares of Taro not currently held by Sun Pharma for $24.50 per share as inadequate and not in the best interests of Taro's minority shareholders.

Taro noted that the Special Committee reached its conclusion after careful consideration, including a thorough review of Taro's business and prospects with its independent financial advisor Citigroup Global Markets Inc. and its independent legal counsel Goldfarb Seligman & Co. as its Israeli legal counsel and Willkie Farr & Gallagher LLP, as its US legal counsel.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stitch Fix, an online personal styling service, has filed for its initial public offering on Nasdaq, expecting to raise $100 million. The company, which was founded in 2011 by Katrina Lake, is reportedly seeking a valuation of up to $4 billion in the IPO. The proposed NASDAQ trading symbol is "SFIX". Play and entertainment company Hasbro, Inc. reported Monday higher profit in its third quarter, benefited by strong revenues in all regions. Both earnings and topline beat market estimates. The improvements were partly offset by negative impact of the Toys"R"Us bankruptcy in the U.S. and Canada. Looking ahead, the company projects higher revenues for the fourth quarter. Dutch consumer electronics giant Philips Electronics NV reported Monday lower attributable net income in its third quarter, while pre-tax income increased. Sales were flat on a reported basis, but grew 4 percent on a comparable basis mainly on growth in China. Further, the company said its outlook for 2017 remains unchanged despite ongoing global uncertainties.
comments powered by Disqus
Follow RTT